Yarrow Bioscience Inc

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

Yarrow Bioscience priced an underwritten public offering of 5,769,231 shares at $26.00 per share, for expected gross proceeds of approximately $150 million. Underwriters hold a 30-day option to buy up to 865,384 additional shares, and the deal is expected to close on September 14, 2026, subject to customary conditions. Net proceeds fund R&D on the pipeline — led by YB-101, a potential first-in-class anti-TSHR monoclonal antibody for Graves' disease and thyroid eye disease — plus general corporate purposes. Jefferies, TD Cowen and Guggenheim Securities are joint book-running managers, with LifeSci Capital as lead manager; the offering draws on an S-3 shelf effective since August 19, 2026.

•1mo ago

Yarrow Bioscience Announces Proposed Underwritten Public Offering

Yarrow Bioscience has commenced an underwritten public offering of common stock, with pre-funded warrants available in lieu of shares for certain investors. Size and price were not disclosed, and underwriters receive a 30-day option to buy up to an additional 15% of shares. Proceeds are earmarked for research and development on Yarrow's pipeline — led by YB-101, a potential first-in-class antibody for Graves' disease and thyroid eye disease — plus general corporate purposes. Jefferies, TD Cowen and Guggenheim Securities are joint book-runners, with LifeSci Capital as lead manager, selling off a shelf registration effective August 19, 2026. As a clinical-stage company funding development through primary equity sales, the raise is dilutive; actual impact depends on pricing terms that have yet to be set.

•1mo ago